secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-153075
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024
--------------------------------------------------------------------------------

- Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.
- Paltusotine: PATHFNDR-2 met primary endpoint – 56% on drug vs 5% placebo achieved IGF-1 ≤1.0xULN (p<0.0001).
- PATHFNDR-1 PRO analysis: paltusotine reduced breakthrough symptom exacerbations vs prior injectable SRLs.
- Long-term ACROBAT Advance: stable IGF-1, symptom control, and safety at up to 42 months.
- Crinetics expects to complete NDA submission for paltusotine in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524153075/0001193125-24-153075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524153075/d823838d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-153075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer